Darwin Ling

Developing extended-release PLG drug formulations takes $10M+ and 5-10 years. We enable drug manufacturers and CROs to shorten formulation discovery time by 30-50% by utilizing our automation and machine learning platform.

Upgrade helps customers move in the right direction with affordable and responsible financial products. Since 2017, we’ve helped over 7.5 million customers access over $42 billion in consumer credit. With a relentless focus on improving our customers financial well-being, we build products that put more money in their pocket and support their journey toward a better financial future. We’re backed by some of the most prominent technology investors and were most recently valued at $7.3B. We’re consistently recognized for our innovative technology, rapid growth, and inclusive culture. Most recently, we were named one of the World’s Top Fintech Companies by CNBC, Best Places to Work by Built In, Best Places to Work by the San Francisco Business Times, Best Startup Employer by Forbes, and America’s Greatest Workplaces by Newsweek. Our technology and products have also earned us spots on the Worlds Top 250 Fintech Companies by CNBC, Deloitte Technology Fast 500, and Fintech Breakthrough Awards. We’re looking for new team members who get excited about designing and delivering new and better products. Come join us and help build a better financial future for millions of people.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Aether Biomachines is an American artificial intelligence company that discovers proteins with high-impact, real-world applications. At the core of its work is a Protein Function Model that can unlock new proteins for novel functions. Aether’s AI is being built on an entirely proprietary dataset developed in-house through advanced high-throughput screening and innovative assay technology. Using this platform, Aether has developed seven new classes of proteins with capabilities ranging from refining metals at lower cost and breaking down persistent “forever chemicals” to producing industry-leading materials, enabling complex pharmaceutical manufacturing, recycling plastics, and capturing carbon dioxide. Aether is already translating its AI breakthroughs into practice, commercializing high-performance materials that can print ten times faster than current industry benchmarks while offering superior strength for the defense and aerospace industries.

Serve Robotics (NASDAQ:SERV) develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. The company has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets. Come join us, we are hiring!

Pragma Bio exists to find cures for undruggable immunological disorders. We use real-world data and synthetic biology to map out multi-layered biological signatures associated with clinical outcomes in order to produce natural chemistry with therapeutic potential.

Keatext is a text and sentiment analysis platform that helps you easily build a 360-degree view of your customer feedback and prioritize where to improve customer experience.

Keatext is a text and sentiment analysis platform that helps you easily build a 360-degree view of your customer feedback and prioritize where to improve customer experience.

Mekonos is a Silicon Valley Venture-backed Life Sciences company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in cell & gene therapies and cell line development.

Uplift is the leading Buy Now, Pay Later solution serving the world’s top enterprise brands. Through personalized, flexible payment options, Uplift helps people get more out of life, one thoughtful purchase at a time. Uplift’s enterprise-ready offer engine matches consumers with the right payment plan at the right time, helping brands unlock higher conversion while building customer loyalty. Uplift’s complete range of flexible payment solutions are offered by leading brands throughout the United States and Canada.

Stellic is a unified degree management platform that empowers today’s students to seamlessly plan out their best fit degree path. It keeps advisors less busy and more informed, and delivers data-backed insights all across campus.

Bringing the world closer through Play.

The Angel Collective is a dynamic network of passionate investors dedicated to empowering visionary entrepreneurs. We bridge the gap between ambitious startups and the resources they need to thrive. What We Do: We connect experienced angel investors with high-potential startups across various industries. For Investors: Access a curated pipeline of exciting early-stage ventures. Leverage the collective knowledge and expertise of our network. Invest alongside a community that shares your passion for innovation. For Startups: Gain access to crucial funding to propel your business forward. Receive valuable mentorship and guidance from seasoned investors. Tap into a network of potential customers, partners, and advisors. Why Choose The Angel Collective? Collaborative Spirit: We foster a supportive environment where investors and entrepreneurs can connect, share ideas, and achieve mutual success. Strategic Investment: Our members have a proven track record of identifying and supporting promising startups with high growth potential. Investor Expertise: Our diverse network offers a wealth of experience across various industries and business functions. Focus on Innovation: We are driven by a passion for fostering breakthrough ideas and shaping the future of business. Join Us and Make a Difference The Angel Collective is more than just an investment network. Its a community of passionate individuals working together to unlock the potential of tomorrows game-changers.

SoFi is a values-driven company on a mission to help our members get their money right. We create modern financial products and services that help people borrow, save, spend, invest, and protect their money better, so that they can achieve financial independence and realize their ambitions—from owning a home to saving for retirement, paying off their student loans, and more. CFL #6054612; NMLS #1121636 (www.nmlsconsumeraccess.org) Advisory services through SoFi LLC, a registered investment advisor. SoFi Checking and Savings is offered through SoFi Bank, N.A. Member FDIC. SoFi Money™ is offered through SoFi Securities LLC, member FINRA/SIPC.

Developing extended-release PLG drug formulations takes $10M+ and 5-10 years. We enable drug manufacturers and CROs to shorten formulation discovery time by 30-50% by utilizing our automation and machine learning platform.

Upgrade helps customers move in the right direction with affordable and responsible financial products. Since 2017, we’ve helped over 7.5 million customers access over $42 billion in consumer credit. With a relentless focus on improving our customers financial well-being, we build products that put more money in their pocket and support their journey toward a better financial future. We’re backed by some of the most prominent technology investors and were most recently valued at $7.3B. We’re consistently recognized for our innovative technology, rapid growth, and inclusive culture. Most recently, we were named one of the World’s Top Fintech Companies by CNBC, Best Places to Work by Built In, Best Places to Work by the San Francisco Business Times, Best Startup Employer by Forbes, and America’s Greatest Workplaces by Newsweek. Our technology and products have also earned us spots on the Worlds Top 250 Fintech Companies by CNBC, Deloitte Technology Fast 500, and Fintech Breakthrough Awards. We’re looking for new team members who get excited about designing and delivering new and better products. Come join us and help build a better financial future for millions of people.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Aether Biomachines is an American artificial intelligence company that discovers proteins with high-impact, real-world applications. At the core of its work is a Protein Function Model that can unlock new proteins for novel functions. Aether’s AI is being built on an entirely proprietary dataset developed in-house through advanced high-throughput screening and innovative assay technology. Using this platform, Aether has developed seven new classes of proteins with capabilities ranging from refining metals at lower cost and breaking down persistent “forever chemicals” to producing industry-leading materials, enabling complex pharmaceutical manufacturing, recycling plastics, and capturing carbon dioxide. Aether is already translating its AI breakthroughs into practice, commercializing high-performance materials that can print ten times faster than current industry benchmarks while offering superior strength for the defense and aerospace industries.

Serve Robotics (NASDAQ:SERV) develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. The company has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets. Come join us, we are hiring!